Legend Biotech: The Kelonia Read-Through
What Lilly’s Kelonia Deal Implies About a Stock the Market Has Written Off
This will be a “best ideas only” bio substack providing actionable, highly digestible and high conviction value to investors focused on quality not quantity. Disclaimer: Nothing in this article (or substack) is considered investment advice and is solely the opinion of the author.
*PT Below*
What Lilly Did This Morning
Eli Lilly announced it is acquiring Kelonia Therapeutics for $3.25 billion in cash upfront, with up to $3.75 billion in additional milestones, a potential $7 billion deal. Kelonia’s lead program, KLN-1010, is an in-vivo BCMA CAR-T for multiple myeloma. It is in Phase 1, with first clinical data presented at ASH in December 2025.
That is the factual anchor. Whatever conclusions one draws from it, the reference point for the rest of this post is that a large-cap pharma was willing to write a $3.25B upfront cheque for a pre-commercial, Phase 1 BCMA CAR-T program earlier today.
For context, Legend Biotech (NASDAQ: LEGN), which owns 50% of the profits of the only approved BCMA CAR-T on the market (a product doing approximately $1.9 billion in 2025 global sales) closed last Thursday at a market cap of roughly $3.9 billion. LEGN is up roughly 11% today on the Kelonia news, which brings market cap to somewhere in the $4.3 billion range.
Whether that is a pricing error or a rational discount for real risks is the question worth working through.